US2010249145A1PendingUtilityA1
Inhibitors of VEGF Receptor and HGF Receptor Signaling
Est. expiryMay 20, 2025(expired)· nominal 20-yr term from priority
Inventors:Oscar Mario SaavedraStephen William ClaridgeLijie ZhanFranck RaeppelArkadii VaisburgStephane RaeppelRobert DezielMichael MannionNancy Z. ZhouLjubomir Isakovic
A61P 43/00C07D 495/04A61P 35/00A61P 9/00A61K 31/519A61K 31/522A61K 31/4365
41
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
The invention relates to the inhibition of VEGF receptor signaling and HGF receptor signaling. The invention provides compounds and methods for inhibiting VEGF receptor signaling and HGF receptor signaling. The invention also provides compositions and methods for treating cell proliferative diseases and conditions
Claims
exact text as granted — not AI-modified1 . A hydrate or solvate of a compound selected from the group consisting of
2 . The hydrate or solvate according to claim 1 , wherein the compound has the structure
3 . The hydrate or solvate according to claim 1 , wherein the compound has the structure
4 . The hydrate or solvate according to claim 1 , wherein the compound has the structure
5 . The hydrate or solvate according to claim 1 , wherein the compound has the structure
6 . The hydrate or solvate according to claim 1 , wherein the compound has the structure
7 . The hydrate or solvate according to claim 1 , wherein the compound has the structure
8 . The hydrate or solvate according to claim 1 , wherein the compound has the structure
9 . The hydrate or solvate according to claim 1 , wherein the compound has the structure
10 . The hydrate or solvate according to claim 1 , wherein the compound has the structure
11 . The hydrate or solvate according to claim 1 , wherein the compound has the structure
12 . The hydrate or solvate according to claim 1 , wherein the compound has the structure
13 . The hydrate or solvate according to claim 1 , wherein the compound has the structure
14 . The hydrate or solvate according to claim 1 , wherein the compound has the structure
15 . The hydrate or solvate according to claim 1 , wherein the compound has the structure
16 . The hydrate or solvate according to claim 1 , wherein the compound has the structure
17 . The hydrate or solvate according to claim 1 , wherein the compound has the structure
18 . The hydrate or solvate according to claim 1 , wherein the compound has the structure
19 . The hydrate or solvate according to claim 1 , wherein the compound has the structure
20 . The hydrate or solvate according to claim 1 , wherein the compound has the structure
21 . The hydrate or solvate according to claim 1 , wherein the compound has the structure
22 . The hydrate or solvate according to claim 1 , wherein the compound has the structure
23 . The hydrate or solvate according to claim 1 , wherein the compound has the structure
24 . The hydrate or solvate according to claim 1 , wherein the compound has the structure
25 . The hydrate or solvate according to claim 1 , wherein the compound has the structure
26 . The hydrate or solvate according to claim 1 , wherein the compound has the structure
27 . A pharmaceutical composition comprising a hydrate or solvate according to claim 1 and a pharmaceutically acceptable carrier.
28 . A method of inhibiting VEGF receptor signaling and HGF receptor signaling in an animal, the method comprising administering to the animal a receptor inhibiting amount of a hydrate or solvate according to claim 1 , or a composition thereof.
29 . A method of treating an angiogenesis-mediated cell proliferative disease in a patient or inhibiting solid tumor growth in a patient, the method comprising administering to the patient in need thereof an effective therapeutical amount of a hydrate or solvate according to claim 1 or a composition thereof.Cited by (0)
No later patents cite this yet.
References (0)
No backward citations on record.